These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23016437)

  • 1. [Research progress of abnormal phosphorylation of microtubule-associated tau protein and of the targeted inhibition of the phosphorylation].
    Zhou F; Chen S; Sun X
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2012 Aug; 29(4):788-92. PubMed ID: 23016437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration.
    Wang JZ; Grundke-Iqbal I; Iqbal K
    Eur J Neurosci; 2007 Jan; 25(1):59-68. PubMed ID: 17241267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tau therapeutic strategies for the treatment of Alzheimer's disease.
    Churcher I
    Curr Top Med Chem; 2006; 6(6):579-95. PubMed ID: 16712493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants.
    Flaherty DB; Soria JP; Tomasiewicz HG; Wood JG
    J Neurosci Res; 2000 Nov; 62(3):463-72. PubMed ID: 11054815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tau protein phosphatases in Alzheimer's disease: the leading role of PP2A.
    Martin L; Latypova X; Wilson CM; Magnaudeix A; Perrin ML; Terro F
    Ageing Res Rev; 2013 Jan; 12(1):39-49. PubMed ID: 22771380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropathogenic role of adenylate kinase-1 in Aβ-mediated tau phosphorylation via AMPK and GSK3β.
    Park H; Kam TI; Kim Y; Choi H; Gwon Y; Kim C; Koh JY; Jung YK
    Hum Mol Genet; 2012 Jun; 21(12):2725-37. PubMed ID: 22419736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons.
    Padmanabhan J; Levy M; Dickson DW; Potter H
    Brain; 2006 Nov; 129(Pt 11):3020-34. PubMed ID: 16987932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of tau proteolysis by phosphatases.
    Lee S; Shea TB
    Brain Res; 2013 Feb; 1495():30-6. PubMed ID: 23159717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology.
    Griffin RJ; Moloney A; Kelliher M; Johnston JA; Ravid R; Dockery P; O'Connor R; O'Neill C
    J Neurochem; 2005 Apr; 93(1):105-17. PubMed ID: 15773910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau protein kinases: involvement in Alzheimer's disease.
    Martin L; Latypova X; Wilson CM; Magnaudeix A; Perrin ML; Yardin C; Terro F
    Ageing Res Rev; 2013 Jan; 12(1):289-309. PubMed ID: 22742992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Tau Hyperphosphorylation
    Turab Naqvi AA; Hasan GM; Hassan MI
    Curr Top Med Chem; 2020; 20(12):1059-1073. PubMed ID: 31903881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases.
    Mazanetz MP; Fischer PM
    Nat Rev Drug Discov; 2007 Jun; 6(6):464-79. PubMed ID: 17541419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helicobacter pylori filtrate induces Alzheimer-like tau hyperphosphorylation by activating glycogen synthase kinase-3β.
    Wang XL; Zeng J; Yang Y; Xiong Y; Zhang ZH; Qiu M; Yan X; Sun XY; Tuo QZ; Liu R; Wang JZ
    J Alzheimers Dis; 2015; 43(1):153-65. PubMed ID: 25079798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau phosphorylation and aggregation in Alzheimer's disease pathology.
    Avila J
    FEBS Lett; 2006 May; 580(12):2922-7. PubMed ID: 16529745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease.
    Gong CX; Iqbal K
    Curr Med Chem; 2008; 15(23):2321-8. PubMed ID: 18855662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association of microtubule promoting and binding activity of tau with its phosphorylation sites].
    Wang J; Wei Z; Wang Q; Grundke-Iqbal I; Iqbal K
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2000 Apr; 22(2):120-3. PubMed ID: 12903511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro analysis of tau phosphorylation sites and its biological activity.
    Wang J; Wang X; Liu R; Wang Q; Grundke-Iqbal I; Iqbal K
    Chin Med Sci J; 2002 Mar; 17(1):13-6. PubMed ID: 12894878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.
    Onishi T; Iwashita H; Uno Y; Kunitomo J; Saitoh M; Kimura E; Fujita H; Uchiyama N; Kori M; Takizawa M
    J Neurochem; 2011 Dec; 119(6):1330-40. PubMed ID: 21992552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau phosphorylation: physiological and pathological consequences.
    Stoothoff WH; Johnson GV
    Biochim Biophys Acta; 2005 Jan; 1739(2-3):280-97. PubMed ID: 15615646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila.
    Nishimura I; Yang Y; Lu B
    Cell; 2004 Mar; 116(5):671-82. PubMed ID: 15006350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.